nr2d

QNZ46 是一种 NR2C NR2D 选择性 NMDA 受体非竞争性拮抗剂。

(3S,6R)-NML 是一种 NMDA 受体拮抗剂，pIC50值为 4.8 (GluN1-GluN2A)、4.6 (GluN1-GluN2B)、5.0 (GluN1-GluN2C) 和 5.0 (GluN1-GluN2D)。(3S,6R)-NML 适用于抑郁症的研究。

NMDA receptor potentiator-1 (Compound 1368) 是一种亚基选择性的 NMDA receptor 增强剂。NMDA receptor potentiator-1 对 NR2C 和 NR2D 表达的 IC50 值分别为 4 μM 和 5 μM。

CIQ 是亚基选择性NMDA 受体增强剂，可作用于NR2C 或NR2D 亚基。

N-Methyl-D-aspartate (NMDA) receptors are Ca2+ permeable ligand-gated channels of the central nervous system that are activated after binding of the co-agonists glutamate and glycine. CAY10608 is a propanolamine that potently, selectively, and non-competitively antagonizes the NR2B subunit of NMDA receptors (IC50 = 50 nM). It does not inhibit NR1, NR2A, NR2C, and NR2D subunits and has no significant effects on α-amino-3-hydroxy-5-methyl-4-isoxazolepropioinic acid (AMPA) or kainate receptors. CAY10608 is neuroprotective, since it prevents NMDA-triggered release of lactate dehydrogenase from cultured cortical neurons. Also, CAY10608, when administered intraperitoneally, reduces brain infarct volume resulting from transient ischemia via carotid artery occlusion.